Last reviewed · How we verify

Deferasirox, Vitamin D and Azacitidine

Groupe Francophone des Myelodysplasies · Phase 1 active Small molecule

Deferasirox, Vitamin D and Azacitidine is a Small molecule drug developed by Groupe Francophone des Myelodysplasies. It is currently in Phase 1 development. Also known as: Exjade, VitaminD, Vidaza.

At a glance

Generic nameDeferasirox, Vitamin D and Azacitidine
Also known asExjade, VitaminD, Vidaza
SponsorGroupe Francophone des Myelodysplasies
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Deferasirox, Vitamin D and Azacitidine

What is Deferasirox, Vitamin D and Azacitidine?

Deferasirox, Vitamin D and Azacitidine is a Small molecule drug developed by Groupe Francophone des Myelodysplasies.

Who makes Deferasirox, Vitamin D and Azacitidine?

Deferasirox, Vitamin D and Azacitidine is developed by Groupe Francophone des Myelodysplasies (see full Groupe Francophone des Myelodysplasies pipeline at /company/groupe-francophone-des-myelodysplasies).

Is Deferasirox, Vitamin D and Azacitidine also known as anything else?

Deferasirox, Vitamin D and Azacitidine is also known as Exjade, VitaminD, Vidaza.

What development phase is Deferasirox, Vitamin D and Azacitidine in?

Deferasirox, Vitamin D and Azacitidine is in Phase 1.

Related